- MediPharm (LABS) has signed a research agreement with the Keck School of Medicine of the University of Southern California (USC)
- The research will evaluate the efficacy of THC and CBD to treat hospice-eligible patients with dementia experiencing agitation
- MediPharm will supply the study drugs and the placebo
- The trial seeks to minimize the undesirable side effects from the antipsychotics, sedatives and opiates typically prescribed to these patients
- MediPharm Labs develops and manufactures pharmaceutical-grade cannabis concentrates, active pharmaceutical ingredients and advanced derivative products
- MediPharm (LABS) closed down by 10 per cent trading at $0.09 per share
MediPharm (LABS) has signed a research agreement with USC’s Keck School of Medicine.
The research involves a randomized double-blind placebo-controlled phase 2 trial on the efficacy of THC and CBD to treat hospice-eligible patients with dementia experiencing agitation.
The 12-week multicenter study will evaluate an oral THC/CBD combination at week 2 and secondary outcomes at week 12. Researchers will recruit approximately 150 participants from 20 clinical trial sites in the U.S. over a two-year period.
The trial seeks to minimize the undesirable side effects from the antipsychotics, sedatives and opiates typically prescribed for agitation in dementia patients.
MediPharm will supply the study drugs and the placebo.
The lead investigators – Jacobo Mintzer, MD, MBA, Brigid Reynolds, ANP-BC, and the Alzheimer’s Clinical Trial Consortium – won a US$16M grant from the U.S. National Institutes of Health and the National Institute on Aging to support the project.
According to the Alzheimer’s Association, approximately half of those diagnosed with Alzheimer’s or other types of dementia will receive hospice care at the end of their life.
There are currently no approved treatments or guidelines for clinicians to address end-of-life agitation in dementia.
“We are proud to participate in this important research that further solidifies our pharmaceutical approach to medical cannabis,” stated David Pidduck, MediPharm’s CEO. “MediPharm has invested in the infrastructure, licensing and expertise to become the preferred partner for pharmaceutical companies looking to add drugs containing cannabis to their pipelines.”
MediPharm Labs develops and manufactures pharmaceutical-grade cannabis concentrates, active pharmaceutical ingredients and advanced derivative products.
MediPharm (LABS) closed down by 10 per cent trading at $0.09 per share.
